Clinical features and prognosis for anaplastic large cell lymphoma / 中南大学学报(医学版)
Journal of Central South University(Medical Sciences)
;
(12): 631-637, 2018.
Artículo
en Chino
| WPRIM
| ID: wpr-813217
ABSTRACT
To determine clinical and pathologic profiles for anaplastic large cell lymphoma (ALCL).
Methods:
The clinical data of 22 patients with ALCL were analyzed retrospectively. Therapentie effect of different treatment strategies on ALCL was evaluated.Results:
The median age for these patients was 32(9-70) years old and the patients with positive ALK accounted for 68.2% (15/22). All patients underwent chemotherapy, including regiments of CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), CHOPE (CHOP plus etoposide) or BEACOP (CHOP plus etoposide and bleomycin). Fourteen (63.6%) patients achieved initial complete remission (CR) and the CR rate for patients with ALK+ was significantly higher than that of patients with ALK- (P0.05). After a median follow-up of 41 (2-150) months, 12 patients were overall survival, the median progression free time was 22.5 (2-150) months, and the age, gender, stage, IPI index, ALK expression level, beta 2-MG level, LDH level, and B symptoms had no significant effect on the rate of overall survival (P>0.05).Conclusion:
ALK-positive occurs mainly in ALCL patients. The chemotherapy is still the main treatment, and CHOPE regimen is a better initial treatment scheme because the most patients show good prognosis.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Pronóstico
/
Vincristina
/
Bleomicina
/
Prednisona
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Doxorrubicina
/
Factores Sexuales
/
Estudios Retrospectivos
/
Mortalidad
/
Factores de Edad
Tipo de estudio:
Estudio observacional
/
Estudio pronóstico
Límite:
Adolescente
/
Adulto
/
Anciano
/
Niño
/
Femenino
/
Humanos
/
Masculino
Idioma:
Chino
Revista:
Journal of Central South University(Medical Sciences)
Año:
2018
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS